METAVIA INC. reports a Return on Equity (ROE) of -144.66%.

What is MTVA's dividend yield?

METAVIA INC. offers a dividend yield of 0.00%.

What is MTVA's Deepscope Quality Score?

Deepscope rates MTVA's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy MTVA?

Deepscope's AI Timing Score for MTVA is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does MTVA belong to?

METAVIA INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

หุ้น MTVA (NASDAQ) | METAVIA INC. – วิเคราะห์โดย Deepscope

Stock Check ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.
(Price: 2026-06-09 | FS: 2026-03-31)

MTVA

METAVIA INC.

US:NASDAQ STOCK Healthcare >> Biotechnology News 87

USD 1.89

-0.33 (-14.86%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-144.7%

ROE

-91.2%

ROA

0.00%

Div Yield

METAVIA INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.89 Price -0.33 (-14.86%) Day Change	NEWS SCORE: 87

MTVA มีคุณภาพโดยรวมไม่ดี ( คะแนนปัจจัยพื้นฐาน = 46) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราผลตอบแทนสินทรัพย์ (ROA) ค่อนข้างต่ำเมื่อเทียบกับอัตราผลตอบแทนผู้ถือหุ้น(ROE)
อัตราการเติบโตของอัตราผลตอบแทนสินทรัพย์(ROA) ปัจจุบันต่ำกว่าเกณฑ์
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร ไม่ดี , ...

ปัจจัยทางคุณภาพ

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	87
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.89
PBV / Sector	1.46 / 4.71 GOOD
Earning Per Share	-1.87

PE / Sector	N/A / 17.58
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	29.30 M GREAT
Average 1W Daily Value	9.60 M

ปัจจัยทางเทคนิค

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

สุขภาพทางการเงิน

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ประสิทธิภาพการทำกำไร

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 468.85
NPM Average (%) / Sector	N/A / -1,531.69
NPM Change Average (%) / Sector	N/A / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-91.22 / 31.69
ROA Average (%) / Sector	-75.21 / -353.18
ROA Change Average (%) / Sector	134.63 / 5,214.65 GREAT
ROE (%) / Sector	-144.66 / 10.58
ROE Average (%) / Sector	-174.95 / 27.64
ROE Change Average (%) / Sector	77.82 / 2,048.88 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

ผลตอบแทนต่อผู้ถือหุ้น

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 3.68

รายละเอียดการจดทะเบียน

Analyze Date	2026-06-10 09:43:16
Symbol	MTVA
Name	METAVIA INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	5.16 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	13.27 / 8,889.42

ข่าว, ประมาณการ, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 545 Concord Avenue, Cambridge, MA, United States, 02138

Phone: 857 702 9600

Website: https://www.metaviatx.com

Sector: Healthcare >> Biotechnology

Description: MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.